Teva Pharmaceutical Reports Positive Topline Data for Anti-IL-15 Drug in Celiac Disease

MT Newswires Live

09/02

Teva Pharmaceutical's (TEVA) investigational anti-IL-15 antibody TEV '408 met the primary endpoint in an ongoing Phase 2a study in adults with celiac disease, the company said Wednesday.

The company said a single subcutaneous dose of TEV '408 demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8.

TEV '408 was well tolerated with no emerging safety signals, and additional analyses are underway, with further data expected to be presented at a future scientific meeting, Teva added.

Teva Pharmaceutical shares were up 4.8% in premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2664638819"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664638819\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664638819?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 19:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664638819","market":"us","top_or_hot":-1,"title":"Teva Pharmaceutical Reports Positive Topline Data for Anti-IL-15 Drug in Celiac Disease","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical's (TEVA) investigational anti-IL-15 antibody TEV '408 met the primary endpoint in an ongoing Phase 2a study in adults with celiac disease, the company said Wednesday.</p><p>The company said a single subcutaneous dose of TEV '408 demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8.</p><p>TEV '408 was well tolerated with no emerging safety signals, and additional analyses are underway, with further data expected to be presented at a future scientific meeting, Teva added.</p><p>Teva Pharmaceutical shares were up 4.8% in premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical Reports Positive Topline Data for Anti-IL-15 Drug in Celiac Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical Reports Positive Topline Data for Anti-IL-15 Drug in Celiac Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-02 19:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical's (TEVA) investigational anti-IL-15 antibody TEV '408 met the primary endpoint in an ongoing Phase 2a study in adults with celiac disease, the company said Wednesday.</p><p>The company said a single subcutaneous dose of TEV '408 demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8.</p><p>TEV '408 was well tolerated with no emerging safety signals, and additional analyses are underway, with further data expected to be presented at a future scientific meeting, Teva added.</p><p>Teva Pharmaceutical shares were up 4.8% in premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664638819","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664638819","pubTimestamp":1788349900,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical's  investigational anti-IL-15 antibody TEV '408 met the primary endpoint in an ongoing Phase 2a study in adults with celiac disease, the company said Wednesday.The company said a single subcutaneous dose of TEV '408 demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8.TEV '408 was well tolerated with no emerging safety signals, and additional analyses are underway, with further data expected to be presented at a future scientific meeting, Teva added.Teva Pharmaceutical shares were up 4.8% in premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4584":"避孕概念","BK4566":"资本集团","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","TEVA":"梯瓦制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4559":"巴菲特持仓","BK4557":"大麻股","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4596":"哈里斯概念"},"translate_title":"梯瓦制药报告抗 IL-15 药物治疗乳糜泻的积极顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5},"content_text":"Teva Pharmaceutical's (TEVA) investigational anti-IL-15 antibody TEV '408 met the primary endpoint in an ongoing Phase 2a study in adults with celiac disease, the company said Wednesday.The company said a single subcutaneous dose of TEV '408 demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8.TEV '408 was well tolerated with no emerging safety signals, and additional analyses are underway, with further data expected to be presented at a future scientific meeting, Teva added.Teva Pharmaceutical shares were up 4.8% in premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}